Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations

Surgery for Obesity and Related Diseases

Volumn 12, Issue 6, 2016, Pages 1144-1162

  Rubino, Francesco ^a   Nathan, David M ^b   Eckel, Robert H ^c   Schauer, Philip R ^d   Alberti, K George M M ^e   Zimmet, Paul Z ^f   Del Prato, Stefano ^g   Ji, Linong ^h   Sadikot, Shaukat M ⁱ   Herman, William H ^j   Amiel, Stephanie A ^a   Kaplan, Lee M ^b   Taroncher Oldenburg, Gaspar ^k   Cummings, David E ^l  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF PISA   (Italy)

^h PEKING UNIVERSITY   (China)

ⁱ DiabetesIndia   (India)

^j UNIVERSITY OF MICHIGAN   (United States)

^k University of Washington ^*  (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; ASIAN; BARIATRIC SURGERY; BODY MASS; CARDIOVASCULAR RISK; CONSENSUS; DELPHI STUDY; GASTROINTESTINAL TRACT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; ADVERSE EFFECTS; AFTERCARE; CLINICAL DECISION MAKING; CONSENSUS DEVELOPMENT; DIABETES MELLITUS, TYPE 2; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; LAPAROSCOPY; OBESITY, MORBID; PATIENT SAFETY; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROCEDURES; SURGICAL EQUIPMENT;

AFTERCARE; BARIATRIC SURGERY; CLINICAL DECISION-MAKING; CONSENSUS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; LAPAROSCOPY; OBESITY, MORBID; PATIENT SAFETY; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; SURGICAL INSTRUMENTS;

EID: 84995477509     PISSN: 15507289     EISSN: 18787533     Source Type: Journal    
DOI: 10.1016/j.soard.2016.05.018     Document Type: Article

References (104)

1. [1] Leyton, O., Diabetes and operation: a note on the effect of gastrojejunostomy upon a case of mild diabetes mellitus with a low renal threshold. Lancet 206 (1925), 1162–1163.
2. [2] Friedman, M.N., Sancetta, A.J., Magovern, G.J., The amelioration of diabetes mellitus following subtotal gastrectomy. Surg Gynecol Obstet 100 (1955), 201–204.
3. [3] Sjöström, L., Lindroos, A.K., Peltonen, M., et al., Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004), 2683–2693.
4. [4] Pories, W.J., Swanson, M.S., MacDonald, K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222 (1995), 339–350 discussion 350–352.
5. [5] Rubino, F., Schauer, P.R., Kaplan, L.M., Cummings, D.E., Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 61 (2010), 393–411.
6. [6] Rubino, F., Marescaux, J., Effect of duodenaljejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239 (2004), 1–11.
7. [7] Rubino, F., Gagner, M., Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236 (2002), 554–559.
8. [8] Rubino, F., Kaplan, L.M., Schauer, P.R., Cummings, D.E., Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 251 (2010), 399–405.
9. [9] Cummings, D.E., Cohen, R.V., Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2 (2014), 175–181.
10. [10] Dixon, J.B., O'Brien, P.E., Playfair, J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299 (2008), 316–323.
11. [11] Mingrone, G., Panunzi, S., De Gaetano, A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366 (2012), 1577–1585.
12. [12] Schauer, P.R., Kashyap, S.R., Wolski, K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366 (2012), 1567–1576.
13. [13] Ikramuddin, S., Korner, J., Lee, W.J., et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309 (2013), 2240–2249.
14. [14] Courcoulas, A.P., Goodpaster, B.H., Eagleton, J.K., et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg 149 (2014), 707–715.
15. [15] Halperin, F., Ding, S.A., Simonson, D.C., et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg 149 (2014), 716–726.
16. [16] Liang, Z., Wu, Q., Chen, B., Yu, P., Zhao, H., Ouyang, X., Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract 101 (2013), 50–56.
17. [17] Wentworth, J.M., Playfair, J., Laurie, C., et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol 2 (2014), 545–552.
18. [18] Parikh, M., Chung, M., Sheth, S., et al. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann Surg 260 (2014), 617–622 discussion 622–624.
19. [19] Schauer, P.R., Bhatt, D.L., Kirwan, J.P., et al., STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 370 (2014), 2002–2013.
20. [20] Mingrone, G., Panunzi, S., De Gaetano, A., et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386 (2015), 964–973.
21. [21] Ikramuddin, S., Billington, C.J., Lee, W.J., et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol 3 (2015), 413–422.
22. [22] Ding, S.A., Simonson, D.C., Wewalka, M., et al. Adjustable gastric band surgery or medical management in patients with type 2 diabetes: a randomized clinical trial. J Clin Endocrinol Metab 100 (2015), 2546–2556.
23. [23] Cummings, D.E., Arterburn, D.E., Westbrook, E.O., et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia 59 (2016), 945–953.
24. [24] Courcoulas, A.P., Belle, S.H., Neiberg, R.H., et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg 150 (2015), 931–940.
25. [25] Gloy, V.L., Briel, M., Bhatt, D.L., et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ, 347, 2013, f5934.
26. [26] Thaler, J.P., Cummings, D.E., Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 150 (2009), 2518–2525.
27. [27] Madsbad, S., Dirksen, C., Holst, J.J., Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol 2 (2014), 152–164.
28. [28] Salehi, M., Woods, S.C., D'Alessio, D.A., Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion. Obesity (Silver Spring) 23 (2015), 2046–2052.
29. [29] Tremaroli, V., Karlsson, F., Werling, M., et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 22 (2015), 228–238.
30. [30] Dirksen, C., Jørgensen, N.B., Bojsen-Møller, K.N., et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 55 (2012), 1890–1901.
31. [31] Breen, D.M., Rasmussen, B.A., Kokorovic, A., Wang, R., Cheung, G.W., Lam, T.K., Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med 18 (2012), 950–955.
32. [32] Ryan, K.K., Tremaroli, V., Clemmensen, C., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509 (2014), 183–188.
33. [33] Liou, A.P., Paziuk, M., Luevano, J.M. Jr, Machineni, S., Turnbaugh, P.J., Kaplan, L.M., Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med, 5, 2013 178ra41.
34. [34] Saeidi, N., Meoli, L., Nestoridi, E., et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 341 (2013), 406–410.
35. [35] Drucker, D.J., The role of gut hormones in glucose homeostasis. J Clin Invest 117 (2007), 24–32.
36. [36] Picot, J., Jones, J., Colquitt, J.L., et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 13 (2009), 1–190 215–357.
37. [37] Keating, C., Neovius, M., Sjöholm, K., et al. Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol 3 (2015), 855–865.
38. [38] Zimmet, P., Alberti, K.G., Rubino, F., Dixon, J.B., IDF's view of bariatric surgery in type 2 diabetes. Lancet 378 (2011), 108–110.
39. [39] Kasama, K., Mui, W., Lee, W.J., et al. IFSO-APC consensus statements 2011. Obes Surg 22 (2012), 677–684.
40. [40] National Institute for Health and Care Excellence. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. 2014, National Institute for Health and Care Excellence, London.
41. [41] National Institute for Health and Care Excellence. Algorithm for blood glucose lowering therapy in adults with type 2 diabetes. 2015, National Institute for Health and Care Excellence, London.
42. [42] Grady D. Surgery for diabetes may be better than standard treatment. The New York Times, 26 March 2012.
43. [43] Consensus Development Conference Panel. NIH conference. Gastrointestinal surgery for severe obesity. Ann Intern Med 115 (1991), 956–961.
44. [44] Burns, P.B., Rohrich, R.J., Chung, K.C., The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg 128 (2011), 305–310.
45. [45] Shekelle, P.G., Woolf, S.H., Eccles, M., Grimshaw, J., Developing clinical guidelines. West J Med 170 (1999), 348–351.
46. [46] Jensen, M.D., Ryan, D.H., Apovian, C.M., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63:25 Pt B (2014), 2985–3023.
47. [47] Dalkey, N., Helmer, O., An experimental application of the DELPHI method to the use of experts. Manage Sci 9 (1963), 458–467.
48. [48] Milholland, A.V., Wheeler, S.G., Heieck, J.J., Medical assessment by a Delphi group opinion technic. N Engl J Med 288 (1973), 1272–1275.
49. [49] Gabel, M.J., Shipan, C.R., A social choice approach to expert consensus panels. J Health Econ 23 (2004), 543–564.
50. [50] Kleynen, M., Braun, S.M., Bleijlevens, M.H., et al. Using a Delphi technique to seek consensus regarding definitions, descriptions and classification of terms related to implicit and explicit forms of motor learning. PLoS One, 9, 2014, e100227.
51. [51] Carlsson, L.M., Peltonen, M., Ahlin, S., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367 (2012), 695–704.
52. [52] Sjöström, L., Peltonen, M., Jacobson, P., et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311 (2014), 2297–2304.
53. [53] Sjöholm, K., Pajunen, P., Jacobson, P., et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia 58 (2015), 1448–1453.
54. [54] Sjöström, L., Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med 273 (2013), 219–234.
55. [55] Cohen, R.V., Pinheiro, J.C., Schiavon, C.A., Salles, J.E., Wajchenberg, B.L., Cummings, D.E., Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 35 (2012), 1420–1428.
56. [56] Arterburn, D.E., Bogart, A., Sherwood, N.E., et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23 (2013), 93–102.
57. [57] Adams, T.D., Davidson, L.E., Litwin, S.E., et al. Health benefits of gastric bypass surgery after 6 years. JAMA 308 (2012), 1122–1131.
58. [58] Brethauer, S.A., Aminian, A., Romero-Talamás, H., et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 258 (2013), 628–636 discussion 636–637.
59. [59] Hsu, C.C., Almulaifi, A., Chen, J.C., et al. Effect of bariatric surgery vs medical treatment on type 2 diabetes in patients with body mass index lower than 35: five-year outcomes. JAMA Surg 150 (2015), 1117–1124.
60. 2. Surg Obes Relat Dis 11 (2015), 6–11.
61. [61] Sjöström, L., Gummesson, A., Sjöström, C.D., et al. Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 10 (2009), 653–662.
62. [62] Sjöström, L., Peltonen, M., Jacobson, P., et al. Bariatric surgery and long-term cardiovascular events. JAMA 307 (2012), 56–65.
63. [63] Sjöström, L., Narbro, K., Sjöström, C.D., et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007), 741–752.
64. [64] Adams, T.D., Gress, R.E., Smith, S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 357 (2007), 753–761.
65. [65] Arterburn, D.E., Olsen, M.K., Smith, V.A., et al. Association between bariatric surgery and long-term survival. JAMA 313 (2015), 62–70.
66. [66] Inge, T.H., Courcoulas, A.P., Jenkins, T.M., et al. Teen-LABS Consortium. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 374 (2016), 113–123.
67. [67] Laiteerapong, N., Huang, E.S., The public health implications of the cost-effectiveness of bariatric surgery for diabetes. Diabetes Care 33 (2010), 2126–2128.
68. [68] Hoerger, T.J., Zhang, P., Segel, J.E., Kahn, H.S., Barker, L.E., Couper, S., Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care 33 (2010), 1933–1939.
69. [69] CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 (2002), 2542–2551.
70. [70] Birkmeyer, J.D., Finks, J.F., O'Reilly, A., et al., Michigan Bariatric Surgery Collaborative. Surgical skill and complication rates after bariatric surgery. N Engl J Med 369 (2013), 1434–1442.
71. [71] Flum, D.R., Belle, S.H., King, W.C., et al., Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 361 (2009), 445–454.
72. [72] Courcoulas, A.P., Christian, N.J., Belle, S.H., et al., Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 310 (2013), 2416–2425.
73. [73] Arterburn, D.E., Courcoulas, A.P., Bariatric surgery for obesity and metabolic conditions in adults. BMJ, 349, 2014, g3961.
74. [74] Young, M.T., Gebhart, A., Phelan, M.J., Nguyen, N.T., Use and outcomes of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass: analysis of the American college of surgeons NSQIP. J Am Coll Surg 220 (2015), 880–885.
75. [75] Aminian, A., Brethauer, S.A., Kirwan, J.P., Kashyap, S.R., Burguera, B., Schauer, P.R., How safe is metabolic/diabetes surgery?. Diabetes Obes Metab 17 (2015), 198–201.
76. [76] Birkmeyer, N.J., Dimick, J.B., Share, D., et al. Michigan Bariatric Surgery Collaborative. Hospital complication rates with bariatric surgery in Michigan. JAMA 304 (2010), 435–442.
77. [77] Altieri M.S., Yang J., Telem D.A., et al. Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York. Surg Endosc. 23 July 2015 [Epub ahead of print]. 〈doi:10.1007/s00464-015-4402-8〉.
78. [78] Hutter, M.M., Schirmer, B.D., Jones, D.B., et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 254 (2011), 410–420 discussion 420–422.
79. [79] Nguyen, N.T., Slone, J.A., Nguyen, X.M., Hartman, J.S., Hoyt, D.B., A prospective randomized trial of laparoscopic gastric bypass versus laparoscopic adjustable gastric banding for the treatment of morbid obesity: outcomes, quality of life, and costs. Ann Surg 250 (2009), 631–641.
80. [80] Morino, M., Toppino, M., Forestieri, P., Angrisani, L., Allaix, M.E., Scopinaro, N., Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg 246 (2007), 1002–1007 discussion 1007–1009.
81. [81] Risstad, H., Søvik, T.T., Engström, M., et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. JAMA Surg 150 (2015), 352–361.
82. [82] Mechanick, J.I., Kushner, R.F., Sugerman, H.J., et al., American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity (Silver Spring) 17:Suppl. 1 (2009), S1–S70.
83. [83] Mechanick, J.I., Youdim, A., Jones, D.B., et al., American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 21:Suppl. 1 (2013), S1–S27.
84. [84] Del Villar Madrigal, E., Neme-Yunes, Y., Clavellina-Gaytan, D., Sanchez, H.A., Mosti, M., Herrera, M.F., Anemia after Roux-en-Y gastric bypass. How feasible to eliminate the risk by proper supplementation?. Obes Surg 25 (2015), 80–84.
85. [85] Flancbaum, L., Belsley, S., Drake, V., Colarusso, T., Tayler, E., Preoperative nutritional status of patients undergoing Roux-en-Y gastric bypass for morbid obesity. J Gastrointest Surg 10 (2006), 1033–1037.
86. [86] Lalmohamed, A., de Vries, F., Bazelier, M.T., et al. Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study. BMJ, 345, 2012, e5085.
87. [87] Lu, C.W., Chang, Y.K., Chang, H.H., et al. Fracture risk after bariatric surgery: a 12-year nationwide cohort study. Medicine (Baltimore), 94, 2015, e2087.
88. [88] Lee, C.J., Clark, J.M., Schweitzer, M., et al. Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy. Obesity (Silver Spring) 23 (2015), 1079–1084.
89. [89] Service, G.J., Thompson, G.B., Service, F.J., Andrews, J.C., Collazo-Clavell, M.L., Lloyd, R.V., Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353 (2005), 249–254.
90. [90] Ponce, J., Woodman, G., Swain, J., et al., REDUCE Pivotal Trial Investigators. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 11 (2015), 874–881.
91. [91] Lebovitz, H.E., Ludvik, B., Yaniv, I., Schwartz, T., Zelewski, M., Gutterman, D.D., Metacure Investigators. Treatment of patients with obese type 2 diabetes with Tantalus-DIAMOND gastric electrical stimulation: normal triglycerides predict durable effects for at least 3 years. Horm Metab Res 47 (2015), 456–462.
92. [92] Rohde, U., Hedbäck, N., Gluud, L.L., Vilsbøll, T., Knop, F.K., Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 18 (2016), 300–305.
93. [93] Schouten, R., Rijs, C.S., Bouvy, N.D., et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 251 (2010), 236–243.
94. [94] Iaconelli, A., Panunzi, S., De Gaetano, A., et al. Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care 34 (2011), 561–567.
95. [95] Rubino, F., Shukla, A., Pomp, A., Moreira, M., Ahn, S.M., Dakin, G., Bariatric, metabolic, and diabetes surgery: what's in a name?. Ann Surg 259: (2014), 117–122.
96. [96] Nguyen, K.T., Billington, C.J., Vella, A., et al. Preserved insulin secretory capacity and weight loss are the predominant predictors of glycemic control in patients with type 2 diabetes randomized to Rouxen-Y gastric bypass. Diabetes 64 (2015), 3104–3110.
97. [97] Buse, J.B., Caprio, S., Cefalu, W.T., et al. How do we define cure of diabetes?. Diabetes Care 32 (2009), 2133–2135.
98. [98] Panunzi, S., De Gaetano, A., Carnicelli, A., Mingrone, G., Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg 261 (2015), 459–467.
99. [99] Panunzi, S., Carlsson, L., De Gaetano, A., et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care 39 (2016), 166–174.
100. [100] Eliasson, B., Liakopoulos, V., Franzén, S., et al. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes Endocrinol 3 (2015), 847–854.
101. [101] Müller-Stich, B.P., Senft, J.D., Warschkow, R., et al. Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg 261 (2015), 421–429.
102. [102] Lee, W.J., Chong, K., Ser, K.H., et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 146 (2011), 143–148.
103. [103] Li, J.F., Lai, D.D., Ni, B., Sun, K.X., Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Can J Surg 56 (2013), E158–E164.
104. [104] Lee, W.J., Chong, K., Lin, Y.H., Wei, J.H., Chen, S.C., Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect. Obes Surg 24 (2014), 1552–1562.